88 related articles for article (PubMed ID: 8262744)
1. Manganese dipyridoxal diphosphate-enhanced magnetic resonance imaging in the evaluation of hepatocyte function.
Sidhu MK; Muller HH; Aggeler J; Jones AL; Young SW
Invest Radiol; 1993 Oct; 28(10):903-10. PubMed ID: 8262744
[TBL] [Abstract][Full Text] [Related]
2. MRI measurement of hepatocyte toxicity using the new MRI contrast agent manganese dipyridoxal diphosphate, a manganese/pyridoxal 5-phosphate chelate.
Young SW; Simpson BB; Ratner AV; Matkin C; Carter EA
Magn Reson Med; 1989 Apr; 10(1):1-13. PubMed ID: 2502699
[TBL] [Abstract][Full Text] [Related]
3. Effect of manganese dipyridoxal diphosphate on liver magnetic resonance imaging and serum bilirubin in rats with removable biliary obstruction.
Ni Y; Petré C; Lukito G; Marchal G; Grant D; Gray TJ; Baert AL
Acad Radiol; 1995 Apr; 2(4):300-5. PubMed ID: 9419566
[TBL] [Abstract][Full Text] [Related]
4. The uptake of manganese dipyridoxal-diphosphate by chemically induced hepatocellular carcinoma in rats. A correlation between contrast-media-enhanced magnetic resonance imaging, tumor differentiation, and vascularization.
Ni Y; Marchal G; Zhang X; Van Hecke P; Michiels J; Yu J; Rummeny E; Lodemann KP; Baert AL
Invest Radiol; 1993 Jun; 28(6):520-8. PubMed ID: 8320070
[TBL] [Abstract][Full Text] [Related]
5. Hepatocellular carcinoma: MR imaging with mangafodipir trisodium (Mn-DPDP).
Murakami T; Baron RL; Peterson MS; Oliver JH; Davis PL; Confer SR; Federle MP
Radiology; 1996 Jul; 200(1):69-77. PubMed ID: 8657947
[TBL] [Abstract][Full Text] [Related]
6. Mn-DPDP enhanced MRI in experimental bile duct obstruction.
Marchal G; Ni Y; Zhang X; Yu J; Lodemann KP; Baert AL
J Comput Assist Tomogr; 1993; 17(2):290-6. PubMed ID: 8454757
[TBL] [Abstract][Full Text] [Related]
7. Focal liver lesions: MR imaging with Mn-DPDP--initial clinical results in 40 patients.
Hamm B; Vogl TJ; Branding G; Schnell B; Taupitz M; Wolf KJ; Lissner J
Radiology; 1992 Jan; 182(1):167-74. PubMed ID: 1309218
[TBL] [Abstract][Full Text] [Related]
8. Normal and infarcted myocardium: differentiation with cellular uptake of manganese at MR imaging in a rat model.
Bremerich J; Saeed M; Arheden H; Higgins CB; Wendland MF
Radiology; 2000 Aug; 216(2):524-30. PubMed ID: 10924581
[TBL] [Abstract][Full Text] [Related]
9. Evidence for the dissociation of the hepatobiliary MRI contrast agent Mn-DPDP.
Gallez B; Bacic G; Swartz HM
Magn Reson Med; 1996 Jan; 35(1):14-9. PubMed ID: 8771018
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic enhancement after low-dose infusion of Mn-DPDP.
Gehl HB; Vorwerk D; Klose KC; Günther RW
Radiology; 1991 Aug; 180(2):337-9. PubMed ID: 1906189
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of hepatocyte-specific paramagnetic contrast media for MR imaging of hepatitis.
Tanimoto A; Kreft BP; Baba Y; Zhao L; Finn JP; Compton CC; Stark DD
J Magn Reson Imaging; 1993; 3(5):786-93. PubMed ID: 8400566
[TBL] [Abstract][Full Text] [Related]
12. CT and MR imaging of the liver using liver-specific contrast media. A comparative study in a tumour model.
Leander P; Månsson S; Ege T; Besjakov J
Acta Radiol; 1996 May; 37(3 Pt 1):242-9. PubMed ID: 8845249
[TBL] [Abstract][Full Text] [Related]
13. Comparative assessment of gadoxetate disodium, manganese dipyridoxal diphosphate, and superparamagnetic iron oxide for enhancement of the liver in dogs.
Khangure MS; Hua J
Acad Radiol; 1996 Aug; 3 Suppl 2():S458-60. PubMed ID: 8796629
[No Abstract] [Full Text] [Related]
14. Magnetic resonance imaging after arterial portography with manganese dipyridoxal diphosphate.
Nelson RC; Chezmar JL; Thompson GH; Webber JB; Garrison MH; Spencer HB; Dillehay DL
Invest Radiol; 1993 Apr; 28(4):335-40. PubMed ID: 8478175
[TBL] [Abstract][Full Text] [Related]
15. Hepatocyte-targeted MR contrast agents: contrast enhanced detection of liver cancer in diffusely damaged liver.
Tanimoto A; Kuribayashi S
Magn Reson Med Sci; 2005; 4(2):53-60. PubMed ID: 16340158
[TBL] [Abstract][Full Text] [Related]
16. [The clinical value of Mn-DPDP: a new paramagnetic hepatobiliary contrast medium for magnetic resonance tomography of the liver].
Vogl TJ; Hamm B; Schnell B; Eibl-Eibesfeldt B; Steiner S; Lissner J
Rofo; 1991 Dec; 155(6):568-74. PubMed ID: 1764599
[TBL] [Abstract][Full Text] [Related]
17. MR imaging assessment of experimental hepatic dysfunction with Mn-DPDP.
Coley BD; Mattrey RF; Baker KG; Peterson T; Burgan AR
J Magn Reson Imaging; 1995; 5(1):11-6. PubMed ID: 7696800
[TBL] [Abstract][Full Text] [Related]
18. Cirrhosis of the liver: MR imaging with mangafodipir trisodium (Mn-DPDP).
Murakami T; Baron RL; Federle MP; Peterson MS; Oliver JH; Davis PL; Confer SR
Radiology; 1996 Feb; 198(2):567-72. PubMed ID: 8596867
[TBL] [Abstract][Full Text] [Related]
19. Detection of hepatic malignancies using Mn-DPDP (manganese dipyridoxal diphosphate) hepatobiliary MRI contrast agent.
Young SW; Bradley B; Muller HH; Rubin DL
Magn Reson Imaging; 1990; 8(3):267-76. PubMed ID: 2114511
[TBL] [Abstract][Full Text] [Related]
20. [Manganese-DPDP in the MR tomography of malignant liver tumors. The initial results with a new hepatobiliary contrast agent].
Steudel A; Layer G; Kraheck H; Hartlapp J; Reiser M
Rofo; 1992 May; 156(5):460-4. PubMed ID: 1596550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
